Auro Laboratories Limited

Equities

AUROLAB6

INE292C01011

Pharmaceuticals

Market Closed - Bombay S.E. 03:00:41 2024-05-18 am EDT 5-day change 1st Jan Change
232.1 INR +2.34% Intraday chart for Auro Laboratories Limited -3.77% +79.51%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Auro Laboratories Limited Announces Cessation of Kailash Chand Bubna as Independent Director CI
Auro Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Auro Laboratories Limited Appoints Shaan Jain as Chief Financial Officer CI
Auro Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Auro Laboratories Limited Announces the Resignation of Amit Mahipat Shah as Chief Financial Officer, Effective October 1, 2023 CI
Auro Laboratories Limited Appoints Vishal Kailashchandra Jhunjhunwala as an Non-Executive & Independent Director CI
Auro Laboratories Plans to Spend INR400 Million to Expand Capacity of Metformin HCL Factory MT
Auro Laboratories Limited Announces Intimation Regarding Capacity Expansion CI
Auro Laboratories Limited Announces Resignation of Govardhan Das Agarwal as Director CI
Auro Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Auro Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Auro Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Auro Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Auro Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Auro Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Auro Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Auro Laboratories Limited Announces Management Changes CI
Auro Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Auro Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021 CI
Auro Laboratories Limited Approves the Appointment of Kiran Kulkarni as the Whole-Time Director of the company CI
Auro Laboratories' : Net Profit Surges in Fiscal Q4 MT
Auro Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021 CI
Auro Laboratories Limited Appoints Mrs. Kavita Sharma as Independent Director CI
Auro Laboratories Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020 CI
Auro Laboratories Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020 CI
Chart Auro Laboratories Limited
More charts
Auro Laboratories Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs), intermediates and generic formulations. The Company operates through the Pharmaceuticals segment. It offers APIs under categories, such as antihistamine, muscle relaxant, diuretic, iron deficiency, anti-diabetic, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids anti-inflammatory and others. Its products under intermediates include Glibenclamde Sulphonamide, Cis-bramo benzoate, Cls-Tosylate, 2-Ethoxy Benzoic Acid, 3,4,5, Trimethoxy Benzoic Acid and 5-Bromo Phthalide. It also undertakes toll/custom manufacturing for APIs and Intermediates on contract basis. The Company has a presence in international markets with bulk of its production being exported to Southeast Asia, Middle East and several European Countries. Some of the countries it exports to are Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and United Kingdom.
More about the company
  1. Stock Market
  2. Equities
  3. AUROLAB6 Stock
  4. News Auro Laboratories Limited
  5. Auro Laboratories Plans to Spend INR400 Million to Expand Capacity of Metformin HCL Factory
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW